Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
| ▸ | FLT4 | P35916 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10033771 | 0.91 | ALOX5 (0.45) | DGAT1FAAHFLT1FLT4KDR | |
| SCHEMBL10033773 | 0.91 | KIT (0.45) | DGAT1FAAHKDM4ELMNAPOLB | |
| SCHEMBL2347458 | 0.87 | KIT (0.46) | DGAT1FAAHKDM4ELMNAPOLB | |
| SCHEMBL2343081 | 0.86 | FAAH (0.52) | DGAT1FAAHFLT1FLT4KDR | |
| SCHEMBL10033770 | 0.83 | FLT1 (0.42) | LMNAFLT1FLT4KDR | |
| SCHEMBL2343055 | 0.78 | ALOX5 (0.45) | DGAT1FAAHFLT1FLT4KDR | |
| SCHEMBL2344715 | 0.77 | KIT (0.45) | DGAT1FAAHFLT1FLT4KDR | |
| SCHEMBL10033776 | 0.76 | ALOX5 (0.47) | DGAT1FLT1FLT4KDR | |
| SCHEMBL544248 | 0.73 | ROCK2 (0.52) | LMNAHDAC8 | |
| SCHEMBL10033766 | 0.70 | NPC1 (0.50) | LMNAFLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658659-B2 | Substituted oxazole derivatives and their use as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2014-02-25 | — | — | US | disclosed |
| US-20120108616-A1 | SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | AB SCIENCE | 2012-05-03 | — | — | US | disclosed |
| US-20080242704-A1 | Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors | AB SCIENCE | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242704-A1 | Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors | KIT, TYRO3, LCK | DGAT1 4774/4885FAAH 4292/4885KDM4E 914/4885 |
| US-20120108616-A1 | SUBSTITUTED OXAZOLE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | KIT, FLT3, LTK | DGAT1 4723/4885FAAH 4543/4885KDM4E 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.